AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02041546
Drug: Bolus surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00968253
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
Trial: NCT00968253
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
Trial: NCT00968253
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
Trial: NCT04072354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet dosed once daily
Trial: NCT02090738
Drug: Standard regimen group
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02548962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02100748
Drug: TRV130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 1 - 4 mg will be administered every 4 hours
Trial: NCT02100748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered every 4 hours
Trial: NCT01871571
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01871571
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00865371
Drug: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Trial: NCT01525290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilised powder to be reconstituted as solution indistinguishable from the active drug
Trial: NCT00343356
Drug: Trement
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01323751
Drug: ACY-1215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
Trial: NCT01686230
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.
Trial: NCT01096446
Drug: Intravenous Fat Emulsions
RxNorm normalized name: FAT EMULSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
Trial: NCT02343536
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02193269
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: you will receive 200 mg as a single daily dose for 4 days
Trial: NCT03460392
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Trial: NCT04785755
Drug: Oral standard diuretics therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
Trial: NCT06050343
Drug: Humulin® Regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection at a dose of 0.3 IU / kg
Trial: NCT06050343
Drug: Rinsulin® R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection at a dose of 0.3 IU / kg
Trial: NCT00909766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, once daily, 28 days
Trial: NCT01243437
Drug: doxyxcycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer.
Trial: NCT00696657
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg, once weekly, s.c. injection
Trial: NCT00696657
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg, once weekly, s.c. injection
Trial: NCT00696657
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg, once weekly, s.c. injection
Trial: NCT00696657
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg with titration, once weekly, s.c. injection
Trial: NCT00696657
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg, once weekly, s.c. injection
Trial: NCT04473261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty capsule will be given as placebo
Trial: NCT04220528
Drug: Capecitabine/Tiggio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2).
Trial: NCT00466128
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin 50mg PO followed by 25mg PO q6hrs
Trial: NCT03312777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline powder overencapsulated
Trial: NCT01560546
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/dose/day for 24 weeks
Trial: NCT01560546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo on the skin for 24 weeks
Trial: NCT04423926
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2 d1
Trial: NCT04423926
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 d1
Trial: NCT04423926
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60mg/m2 d1-5
Trial: NCT01441440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
Trial: NCT02929095
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
Trial: NCT00159744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 3 weeks
Trial: NCT04769583
Drug: placebo based quadriple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
Trial: NCT01742624
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03299517
Drug: Antiarrythmic Drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
Trial: NCT01279538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT01803399
Drug: GSK1322322 1200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
Trial: NCT01803399
Drug: GSK1322322 3000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
Trial: NCT01803399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
Trial: NCT00003243
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003243
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02344628
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of two different dosing strategies for the treatment of yaws
Trial: NCT02673593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01762540
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 37.5 mg x1 for 5 days
Trial: NCT01762540
Drug: Calcium Supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01797198
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00174616
Drug: Oxaliplatin, capecitabine, radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks
Trial: NCT03681652
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
Trial: NCT03681652
Drug: Anti-TNF Drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
Trial: NCT01324505
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
Trial: NCT01324505
Drug: Microgyn®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Trial: NCT01031030
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01031030
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01031030
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000494
Drug: indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01977209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02353260
Drug: Docetaxel,Cisplatin,Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
Trial: NCT02064439
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tablet once daily for 12 months
Trial: NCT02064439
Drug: BAY 59-7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablet once daily for 12 months
Trial: NCT00279552
Drug: Recombinant human intrinsic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00938522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
Trial: NCT03437707
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Trial: NCT03437707
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
Trial: NCT04080323
Drug: Dinoprostone 3 mg
RxNorm normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
Trial: NCT02234583
Drug: DS-5565
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-5565 15 mg tablet for oral administration
Trial: NCT04080323
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal tablet of placebo 60 minutes before surgery
Trial: NCT00649012
Drug: Actos® Tablets 45 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45mg, single dose fed
Trial: NCT00752375
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~* Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~* Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy.
Trial: NCT02134314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
Trial: NCT00344682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg - 20mg PO daily over 8 weeks
Trial: NCT00257192
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
Trial: NCT04641364
Drug: recombinant human albumin injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose or multiple doses of intravenous infusion
Trial: NCT04641364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous infusion of 0.9% sodium chloride injection
Trial: NCT00875784
Drug: IMITREX® (4mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
Trial: NCT00875784
Drug: IMITREX® (6mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
Trial: NCT00875784
Drug: IMITREX Tablet 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
Trial: NCT01123278
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone transdermal gel 50 mg/day (5 gr)
Trial: NCT03429543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
Trial: NCT01035255
Drug: LCZ696 200 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 200 mg BID
Trial: NCT01461954
Drug: FST-100 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FST-100 Vehicle
Trial: NCT03575520
Drug: Doxorubicin/Cyclophosphamide(AC) treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks.
Trial: NCT01599468
Drug: saline serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo group received normal saline with the same volumes
Trial: NCT03823417
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion
Trial: NCT03369301
Drug: Gammanorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gammanorm given per standard of care
Trial: NCT03369301
Drug: Other Subcutaneous Immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Subcutaneous Immunoglobulins given per standard of care
Trial: NCT01373567
Drug: TINEFCON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
Trial: NCT00003943
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 gm/m2
Trial: NCT00047281
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00047281
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01727726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet/capsule
Trial: NCT00543829
Drug: doxorubicin, docetaxel, tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
Trial: NCT00543829
Drug: doxorubicin, docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
Trial: NCT06261138
Drug: Transarterial chemoembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
Trial: NCT04072146
Drug: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross over bioavailability study
Trial: NCT03901612
Drug: saline 09%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous post operative regional analgesia